Product Description
Mechanisms of Action: L-Type Calcium Channel Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | China | Egypt | France | Greece | Italy | Korea | Morocco | Portugal | Spain | Thailand | Tunisia | Turkey | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Chiesi
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20200873 | N/A |
Completed |
Hypertension |
2020-10-26 |
|
KUGH15082 (MAAMA) | P4 |
Terminated |
Hypertension |
2018-05-15 |
|
MANTRA | P4 |
Completed |
Hypertension |
2009-02-28 |
|
MANTRA | P3 |
Completed |
Hypertension |
2008-12-01 |